RO7440537
Phase 2
RocheRO7440537 is one of 30 therapeutic programs targeting Huntington disease. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
34 competitors in Huntington Disease
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Actigall
AbbVieApproved
Dojolvi
UltragenyxApproved
Tasigna
AAzurity Pharmaceuticals
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Tricor
JJagotec
Approved
Risperdal
WWim Janssens
Approved
Haldol
DDePuy Orthopaedics
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for RO7440537. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company